DLEC1 Polyclonal Antibody

Rabbit Anti-DLEC1 Polyclonal Antibody

Product Specifications

Background

The cytogenetic location of DLEC1 (deleted in lung and esophageal cancer 1) is 3p21. , and it is located in a region that is commonly deleted in a variety of malignancies. Down-regulation of DLEC1 has been observed in several human cancers including lung, esophageal, renal tumors, and head and neck squamous cell carcinoma. In some cases, reduced expression of DLEC1 in tumor cells is a result of aberrant promoter methylation. Several alternatively spliced transcripts have been observed that contain disrupted coding regions and likely encode nonfunctional proteins.

CAS Number

9007-83-4

Product Name Alternative

DLEC1; DLC1; Deleted in lung and esophageal cancer protein 1; Deleted in lung cancer protein 1; DLC-1

Gene ID

9940

Accession Number

Q9Y238

Reactivity

Human, Rat, Mouse

Immunogen

Synthesized peptide derived from the N-terminal region of human DLEC1 at AA range: 1-80

Clonality

Polyclonal

Tag

Deleted in lung and esophageal cancer protein 1

Applications

IHC, IF, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

DLEC1 Polyclonal Antibody detects endogenous levels of DLEC1 protein.

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:10000; Not yet tested in other applications.